Join to view full profile
810 Jasonway AveSte AColumbus, OH 43214
Phone+1 614-442-3130
Fax+1 614-442-3145
Dr. Bertino is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalResidency, Gastroenterology, 2020 - 2026
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011- Ohio State University HospitalResidency, Internal Medicine, 2004 - 2007
Northeast Ohio Medical UniversityClass of 2004
Certifications & Licensure
OH State Medical License 2004 - 2028
NC State Medical License 2021 - 2022
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer Start of enrollment: 2011 Feb 10
- A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
- Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor
Publications & Presentations
PubMed
- Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy.Adam Khorasanchi, Mingjia Li, Songzhu Zhao, Lai Wei, Evelyn Goodyear
Lung Cancer. 2025-12-01 - 1 citationsPhase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer.Dwight H Owen, Ruohan Wu, Lai Wei, Mikhail Dikov, Shankar Suman
Investigational New Drugs. 2025-12-01 - Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpo...Sandip H Patel, Songzhu Zhao, Mingjia Li, Lai Wei, Marium Husain
Cancer Investigation. 2025-10-01
Journal Articles
- Identifying Patterns of Care for Elderly Patients with Non-Surgically Treated Stage III Non-Small Cell Lung Cancer: An Analysis of the National Cancer DatabaseKai He, Terence M Williams, John C Grecula, Eric D Miller, Erin M Bertino, David P Carbone, Peter G Shields, Jose G Bazan, Karl E Haglund, Gregory A Otterson, BioMed Central
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
